CRISPR gene editing takes on blood cancers: new trial tests donor immune cells
NCT ID NCT05643742
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called CTX112 for people with B-cell cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. CTX112 uses CRISPR gene editing to modify immune cells from a healthy donor, making them target and kill cancer cells. The trial has two phases: first to find the safest dose, then to see how well it works in up to 120 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CTX112 (CRISPR-edited immune cells from a donor)
- What this could lead to
- If it works, this could offer a new treatment option for people with hard-to-treat B-cell cancers that have come back or not responded to other therapies.
- What could go wrong
- This is an early-phase trial with only 120 participants, so the treatment may not work or could cause serious side effects. It is not yet proven safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Alfred Health
RECRUITINGMelbourne, Victoria, 3004, Australia
-
Royal Prince Alfred
RECRUITINGCamperdown, New South Wales, 2050, Australia
-
SCRI
RECRUITINGSan Antonio, Texas, 78229, United States
-
Sir Charles Gairdner Hospital
RECRUITINGNedlands, Western Australia, 6009, Australia
-
University of Kansas
RECRUITINGWestwood, Kansas, 66205, United States
-
University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a targeted drug boost standard therapy for a rare lymphoma?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a targeted drug boost standard chemo for a rare blood cancer?
- Can a second CAR T-Cell infusion beat lymphoma that returns?
- Could a targeted drug boost stem cell transplant success in lymphoma?